ImmunityBio (IBRX) Profit After Tax (2014 - 2026)
ImmunityBio (IBRX) reported Profit After Tax of -$632.8 million for Q1 2026, down 388.08% year-over-year from $219.7 million in Q1 2025, and down 921.31% on a QoQ basis from -$62.0 million in Q4 2025.
ImmunityBio (IBRX) has 13 years of Profit After Tax data on file, last reported at -$632.8 million in Q1 2026.
- Quarterly Profit After Tax fell 388.08% year-over-year to -$632.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$854.6 million (down 108.91% YoY) and the FY2025 annual result came in at -$351.5 million, up 15.01% from the prior year.
- Profit After Tax retreated to -$632.8 million in Q1 2026 per IBRX's latest filing, from -$62.0 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$59.1 million in Q4 2024 and bottomed at -$632.8 million in Q1 2026.
- The 5-year median for Profit After Tax is -$107.6 million (2022), against an average of -$141.1 million.
- The widest annual swing landed in 2024, when Profit After Tax surged 74.68%; it then tumbled 388.08% in 2026.
- Tracing IBRX's Profit After Tax over 5 years: stood at -$107.6 million in 2022, then tumbled by 116.96% to -$233.4 million in 2023, then surged by 74.68% to -$59.1 million in 2024, then slipped by 4.84% to -$62.0 million in 2025, then slumped by 921.31% to -$632.8 million in 2026.
- Per Business Quant, the three latest IBRX Profit After Tax figures stand at -$632.8 million (Q1 2026), -$62.0 million (Q4 2025), and -$67.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn | -632.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -632.78 Mn |
| Dec 31, 2025 | -61.96 Mn |
| Sep 30, 2025 | -67.25 Mn |
| Jun 30, 2025 | -92.57 Mn |
| Mar 31, 2025 | -129.65 Mn |
| Dec 31, 2024 | -59.10 Mn |
| Sep 30, 2024 | -85.73 Mn |
| Jun 30, 2024 | -134.58 Mn |
| Mar 31, 2024 | -134.13 Mn |
| Dec 31, 2023 | -233.39 Mn |
| Sep 30, 2023 | -95.58 Mn |
| Jun 30, 2023 | -138.21 Mn |
| Mar 31, 2023 | -116.58 Mn |
| Dec 31, 2022 | -107.57 Mn |
| Sep 30, 2022 | -111.16 Mn |
| Jun 30, 2022 | -94.84 Mn |
| Mar 31, 2022 | -103.00 Mn |
| Dec 31, 2021 | -91.55 Mn |
| Sep 30, 2021 | -87.63 Mn |
| Jun 30, 2021 | -89.39 Mn |
| Mar 31, 2021 | -80.48 Mn |
| Dec 31, 2020 | -32.13 Mn |
| Sep 30, 2020 | -66.17 Mn |
| Jun 30, 2020 | -51.44 Mn |
| Mar 31, 2020 | -37.04 Mn |
| Dec 31, 2019 | -15.64 Mn |
| Sep 30, 2019 | -15.58 Mn |
| Jun 30, 2019 | -16.68 Mn |
| Mar 31, 2019 | -17.89 Mn |
| Dec 31, 2018 | -17.34 Mn |
| Sep 30, 2018 | -23.64 Mn |
| Jun 30, 2018 | -27.73 Mn |
| Mar 31, 2018 | -27.52 Mn |
| Dec 31, 2017 | -24.49 Mn |
| Sep 30, 2017 | -23.97 Mn |
| Jun 30, 2017 | -23.45 Mn |
| Mar 31, 2017 | -24.52 Mn |
| Dec 31, 2016 | -24.24 Mn |
| Sep 30, 2016 | -31.90 Mn |
| Jun 30, 2016 | -34.00 Mn |
| Mar 31, 2016 | -30.68 Mn |
| Dec 31, 2015 | -26.82 Mn |
| Sep 30, 2015 | -46.31 Mn |
| Jun 30, 2015 | -130.89 Mn |
| Mar 31, 2015 | -32.85 Mn |
| Dec 31, 2014 | -2.76 Mn |
| Sep 30, 2014 | -918,000.00 |
| Jun 30, 2014 | -1.42 Mn |
| Mar 31, 2014 | -1.09 Mn |